Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics (BNGO) showcased its Long String VANTAGE automation solution for Ultra High Molecular Weight DNA extraction at the ESHG 2022 Conference, aimed at enhancing optical genome mapping (OGM) capabilities. The collaboration with Hamilton signifies a major leap in laboratory automation efficiency. The conference featured 13 presentations highlighting OGM's role in identifying rare undiagnosed genetic diseases. CEO Erik Holmlin emphasized the potential benefits of OGM as a cost-effective and rapid alternative to traditional methods.

Bionano Genomics partnered with Hamilton to develop the Long String VANTAGE, an automated system for isolating Ultra High Molecular Weight (UHMW) DNA, enhancing throughput and quality. This innovation allows the extraction of up to 12 UHMW DNA samples in under 4 hours, double the manual output, ensuring high consistency. The collaboration aims to improve optical genome mapping applications and plans to test the system with select clinical laboratories for commercial release by the end of 2022. This automation is expected to enhance workflow efficiency in genomic analysis.

Bionano Genomics (Nasdaq: BNGO) announced a study published in Cell showcasing the effectiveness of optical genome mapping (OGM) in detecting inversions linked to genetic disorders. The research found that 80% of larger detected inversions were balanced and associated with various health issues, including pediatric autism. Analyzing 41 human samples, the study identified 40 recurrent inversions affecting 0.6% of the genome. Erik Holmlin, CEO, emphasized that OGM could make inversion analysis routine in genetic diagnostics.

Bionano Genomics (BNGO) has announced a two-hour presentation on Optical Genome Mapping (OGM) technologies by researchers from leading institutions at the Canadian College of Medical Geneticists (CCMG) General Meeting 2022, scheduled from June 6-10. The workshop, titled New Technologies and Applications of Optical Genome Mapping, will take place on June 8, featuring esteemed presenters from Columbia University Medical Center and University Health Network. This highlights Bionano's commitment to advancing genomic research and applications related to prenatal testing and cancer diagnostics.

Bionano Genomics (BNGO) will actively participate in the AGBT General Meeting 2022 in Orlando, Florida, from June 6-9. Dr. Alka Chaubey, the chief medical officer, will deliver a spotlight presentation on June 8, addressing the integration of Optical Genome Mapping (OGM) and Next Generation Sequencing (NGS) for enhanced genome analysis. Bionano is also a Bronze Sponsor and will host an evening reception, unveiling a partnership with Ignite Worldwide to promote equity in STEM. Attendees can explore live demonstrations of the Saphyr system and NxClinical software.

Bionano Genomics (Nasdaq: BNGO) announced the publication of a peer-reviewed study demonstrating the efficacy of optical genome mapping (OGM) in identifying genetic aberrations in pediatric acute myeloid leukemia (AML). Conducted by researchers at University Hospital Essen, the study analyzed samples from 24 patients, revealing that OGM detected significantly more structural variants (SVs) than traditional methods like FISH. Notably, 32 previously unknown variants were identified, with one being a high-risk marker exclusive to OGM. This research highlights OGM's potential in tracking minimal residual disease (MRD) markers crucial for treatment management.

Bionano Genomics, Inc. (BNGO) will participate virtually in the 2022 H.C. Wainwright Global Investment Conference. The presentation will be available on-demand starting May 24, 2022, at 7:00 a.m. Eastern Time. Erik Holmlin, PhD, President and CEO, will provide a company overview. Bionano specializes in optical genome mapping solutions and diagnostic software, aiming to transform genome analysis in research and medicine. Interested individuals can register for the conference and access the presentation online.

Bionano Genomics (BNGO) is showcasing its full range of cytogenetic research solutions at the American Cytogenomics Conference (ACC) from May 15-18, 2022, in Hilton Head, South Carolina. This year, Bionano exhibits its Optical Genome Mapping (OGM) solutions, NxClinical software, and laboratory services. Six scientific presentations will detail the applications of OGM in prenatal, postnatal testing, and cancer research. The company also plans to host a user spotlight event at Augusta University, highlighting its commitment to advancing genomic analysis.

Bionano Genomics (BNGO) announced the publication of a study from The First Affiliated Hospital of Zhengzhou, Central China's largest hospital, showcasing the advantages of optical genome mapping (OGM) for structural variant analysis. Conducted by Dr. Xiangdong Kong, the study demonstrated OGM's effectiveness in detecting chromosome balanced translocations compared to traditional methods like karyotype analysis and FISH. This innovative approach could enhance preimplantation genetic testing and address recurrent pregnancy loss, an area of significant unmet need in fertility treatment.